Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers.
about
Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient PopulationsOptimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002.Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteersUse of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics.Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infectionBroad-spectrum β-lactams in obese non-critically ill patients.The stereoselective disposition of the enantiomers of ibuprofen in blood, blister and synovial fluidNonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimensClinical pharmacokinetics of cefamandole and ceftazidime administered by continuous intravenous infusion.Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infectionsSynergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.Continuous infusion of beta-lactam antibioticsKilling of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission.Clinical pharmacokinetics and pharmacodynamics of tigecycline.Pharmacokinetics and pharmacodynamics of antibacterial and antifungal agents in adult patients with thermal injury: a review of current literature.Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.Beta-lactam antibiotics: is continuous infusion the preferred method of administration?Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia.Abnormal pharmacokinetics: the need for monitoring.Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.The renal clearance of cefuroxime and ceftazidime and the effect of probenecid on their tubular excretionSputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe.Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis.
P2860
Q28066877-C9428D6F-838E-47FE-A6C1-F069F92144E6Q30939930-B19FF845-5B45-413B-B712-AFF93CF1E3A2Q33676387-76CDFD86-5AFF-4354-A0D9-11A13F48D419Q33692063-27533A8F-5F79-47C4-AE10-03070F5481D2Q33770046-377EBF85-6E38-42B7-94BB-4F1FB1E1E501Q33826261-02ECBEAA-61F0-47EC-9245-11C1378D2C6FQ33839225-4C8E6BBA-F7A8-4544-A7AC-926E02140BAEQ34346269-67EF93D8-0571-4A26-8990-6FA5FBB76325Q34381321-C94AE36D-2F11-45C8-82CB-147B7CDC7AC7Q35013772-46B904D2-2639-4B1A-9539-34BFB8D77541Q35121441-6B23564C-F342-4572-BCEC-D75D0847F494Q35123123-3F615F39-7C9D-4C67-ADF5-515566BA7964Q35131156-8701B5D4-B9F2-4E2D-9EDF-B836E9DD979FQ35656806-5B06FE3B-7751-4A43-9A4D-047BFD5CB5DCQ35820123-24ED7D4B-75C9-4CC2-B363-E388D620D340Q37008814-F3FEF77B-615A-45C1-A4FC-E1CA975D8C50Q37392874-D9F71BB8-4797-4D0E-B80B-F1A6BC1F5083Q37590845-166FFF8D-E80D-41D2-91F4-43FDD702024AQ38244221-D645F2D8-DBBA-49D4-A8AA-8CE41D246223Q38896040-19E8ED66-71A2-4320-B1BD-18A3ED032A15Q40459002-39121375-E867-4FF1-AA40-82E1C17A73F7Q40688395-E875F163-354F-4D0C-8F13-0BDA50D8790AQ40899086-15854CAB-BCEE-42EA-B924-13CD485723F5Q41879559-F20CCD95-F5C5-464C-A3F3-AB80FDF89E4EQ41969706-2BD07D1F-1933-46A8-8D83-EB4469DCBA5EQ44275415-0C5EFD21-E81E-49EA-B28C-6C38F2041B95Q45170003-D4A54BB5-1E79-4D55-80FC-38F9A9556EA1Q54444161-0C3C7760-24D1-4C36-8CA3-D167CFCC500B
P2860
Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers.
description
1990 nî lūn-bûn
@nan
1990 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Pharmacokinetics of ceftazidim ...... fusions in healthy volunteers.
@ast
Pharmacokinetics of ceftazidim ...... fusions in healthy volunteers.
@en
type
label
Pharmacokinetics of ceftazidim ...... fusions in healthy volunteers.
@ast
Pharmacokinetics of ceftazidim ...... fusions in healthy volunteers.
@en
prefLabel
Pharmacokinetics of ceftazidim ...... fusions in healthy volunteers.
@ast
Pharmacokinetics of ceftazidim ...... fusions in healthy volunteers.
@en
P2093
P2860
P356
P1476
Pharmacokinetics of ceftazidim ...... fusions in healthy volunteers.
@en
P2093
P2860
P304
P356
10.1128/AAC.34.12.2307
P407
P577
1990-12-01T00:00:00Z